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SUMMARY 
 
The national family welfare program in India does not currently include injectable 
contraceptives in its mix of contraceptive methods that are offered in public sector clinics.  
Although both types of injectable contraceptives (NetEn and DMPA) are approved for 
commercial sale by the Drug Controller of India and are available with a doctor’s prescription, 
the Ministry of Health and Family Welfare has not begun routine procurement of either 
contraceptive method.  There has not been a large body of research on the use dynamics of 
injectable contraceptives in India that could be used to guide policy decisions on the addition of 
the method.  The few studies that have been conducted indicate positive results and hence 
suggest an important role for the method in the national family planning program.   
 
Pharmacia & Upjohn conducted a “Post Marketing Surveillance Study on Injection Depo-
Provera”1 that was designed to assess the safety and acceptability of DMPA among a sample of 
1,079 women.  The large majority of these women (84.2%) continued with the method through 
five doses.  Side effects were common, as almost 80 percent of the subjects in this study 
reported experiencing one or more medical events during the study period, though only three of 
these cases were considered serious.  The conclusion from this 1999 study is that “DMPA 
150mg is a safe and effective contraceptive, and that sufficient pre-treatment counseling on the 
expected hormonal effects will greatly increase the acceptability of this method of 
contraception” (PMS Final report, page 2). 
 
The Population Council’s Asia and the Near East OR/TA Project conducted an operations 
research study on the effect of price changes on perceptions and use of DMPA in Uttar Pradesh 
in association with Parivar Seva Sanstha in 1998.2  This study examined patterns of use when 
three different prices were charged for the DMPA method in the clinics of an affiliate of Marie 
Stopes International.    Although overall continuation with the method was observed to be low, 
with less than one-fifth (19%) of the women continuing through four doses, users’ perceptions 
were positive and women who could not tolerate a side effect were able to switch to another, 
more acceptable method.  A wholesale price of Rs. 35 was estimated as the most affordable 
price for the DMPA in the setting of this study.  These two studies are the most recent 
investigations into the use dynamics of DMPA in India.  
 
Public debate on injectable contraceptives in India is still characterized by strident rhetoric that 
often polarizes discussions.  This has restrained the implementation of a large-scale, national 
program for injectable contraceptives in India.  However, many public, NGO and private sector 
service delivery systems are suitably matched to the requirements of providing injectable 
contraceptives, including the ability to ensure choice and service delivery quality.   This 
operations research study was designed to demonstrate the feasibility of providing injectable 
contraceptives in private medical practices and to contribute to the body of scientific literature 
on the acceptability of this method in India.  DKT India and EngenderHealth formed a 
partnership with the Population Council’s Frontiers in Reproductive Health program to conduct 
this operations research in Gujarat between July1999 and August 2001. 
 
 
                                                 
1 “Post Marketing Surveillance Study of Injectable Contraceptive Depo-Provera in Indian Women,”  R. P. 
Soonawala, David Zambrano and F. Tam. Pharmacia & Upjohn.  October 8, 1999. New Delhi, India. 
2 “Analysis of Price Change on the Perceptions and Use of DMPA among Clients Using Reproductive Health 
Services in Uttar Pradesh, India.”  Leila Caleb-Varkey, John W. Townsend, Sneh Vishwanath and Sudha 
Tewari.  The Population Council. March 27, 1998. New Delhi, India. 




The DKT social marketing programs in India have been at the forefront of exploring alternative 
contraceptive options and delivery systems.  DKT India is a leader in this field and has a proven 
record in establishing sustainable marketing systems for oral contraceptives and condoms 
(among other products) in several states.  DKT India first included injectable contraceptives in 
its program in mid-1996 when NetEn was piloted in a social marketing project in Maharashtra 
and Gujarat.  In 1999, DKT began to introduce DMPA into its programs in Maharashtra and 
Gujarat.   
 
DKT India contacted approximately 100 private sector providers in Ahmedabad, Baroda and 
Surat (this number was increased by EngenderHealth in the process of arranging for the 
professional seminars) about participating in the study.  In addition to assisting the study in 
identifying participating physicians, DKT India provided an uninterrupted source of DMPA 
injectable contraceptives at a subsidized price of Rs. 40 to their stockists (small, local 
pharmaceutical providers who are associated with the DKT India program).    
 
A key element of this study was to demonstrate that communication practices and DMPA 
counseling could be improved in private practice settings.  This study also sought to determine 
whether a standard level of technical knowledge exists among all the providers in the study.   
 
A partnership was formed with EngenderHealth in India to ensure these two aspects of the study 
and to coordinate the design and implementation of the professional development seminars and 
IEC material production with DKT India and FRONTIERS.  Funds for the EngenderHealth 
organized activities were provided through the Population Council’s Expanding Contraceptive 
Choice program.   
 
EngenderHealth, working with locally recruited and respected consultants, organized eight 
one-day training programs that functioned as a type of professional development seminar for 
the 241 physicians.  Of these, 159 physicians agreed to participate in the operations research 
study at the end of the seminar.  EngenderHealth also conducted one-day training sessions for 
43 DKT India staff between January and May 2000.  These short courses were designed to 
upgrade the technical knowledge and communication skills related to DMPA and to provide 
practical guidance to the DKT India sales force on how to interact with physicians to ensure 
informed choice of DMPA.  In addition to the training programs for physicians and DKT 
India staff, EngenderHealth staff and consultants also conducted follow-up visits between 




The study utilized a post-test only, uncontrolled study design that retrospectively investigated 
the contraceptive practices of all first-time DMPA users in the private practice settings that 
participated in the DKT India social marketing of contraceptives program in Gujarat.  The 
original proposal called for 100 private sector physicians to be enrolled in the study, but once 
field operations began this number was expanded to 158 (in order to achieve a larger sample of 
first-time DMPA users). 
 
Physicians who participated in the study conveyed to all first-time DMPA users a standard 
informed consent statement (written in Gujarati and Hindi) that described the study’s objectives 
and requested permission to conduct a follow-up interview in seven months (i.e., after receiving 
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three doses of DMPA).  DMPA clients were considered eligible for the study if they had never 
used an injectable contraceptive previously (but could have used another contraceptive method), 
were resident in the nearby vicinity of the physician’s practice and had the intention to remain at 
their present address for approximately 9-12 months.  Client enrollment began on April 1, 2000 
and continued through September 30, 2001.  Representatives of CORT collected the client 
enrollment cards on a monthly basis throughout the six-month period.   
 
A subagreement was issued to CORT for the 
organization and conduction of the client and provider 
surveys.  The study’s six-month data collection period 
began fieldwork operations on November 1, 2000 and 
continued without interruption until late January 2001.  
All of the first-time DMPA users who enrolled in the 
study during April-June 2000 and approximately 75 
percent of the 158 providers had been contacted for 
interviews by that date.  On January 26, 2001 a severe 
earthquake occurred in Gujarat, devastating many areas 
of the state and substantially damaging large portions of 
Ahmedabad and Surat, with less physical destruction in 
Baroda.  The earthquake had multiple effects on the 
client follow-up study, primarily through the profound 
disruption to daily life even in the study areas that were 
not directly afflicted with physical destruction.  These 
overwhelming environmental effects on the study caused the follow-up interview period to be 
truncated and the elimination of all clients who had been enrolled between July–October 2001.  
Clients who were enrolled before that time and who were interviewed before the earthquake 
were kept in the study.  The remaining interviews with physicians continued after a pause, as the 
remainder of these cases were in Baroda and other areas less affected by the earthquake, and the 
indicators measured in the provider survey were less likely to be disrupted.   
Limitations to the Study 
 
• Small sample size originally 
predicted was reduced by 
approximately 60 percent due to 
January 2001 earthquake. 
• High lost to follow-up rate 
among clients who remained in 
the study sample limits the 
ability to generalize results. 
• Client background 
characteristics are somewhat 
unique: older, better educated, 









Approximately 88 percent of these physicians (n=139) were successfully contacted and 
completed the interviews during this study.  Overall the physician response rate in the study 
was strong and there is no indication that the missing 12 percent of the original sample in any 
way substantially biases the results that are presented here. 
 
The sample of physicians was nearly evenly divided by gender with 71 of the respondents 
being male and 68 female.  Almost two-thirds (60%, n=83) were OB/GYN specialists and all 
of the others (40%, n=56) were MBBS, or generalists.  Among the OB/GYN specialists 69 
percent were female, whereas most (80%) of the MBBS physicians were male. The average 
length of time that physicians in this sample had been providing medical services was quite 
long (17.4 years).  In general the sample is almost evenly divided between physicians who 
prescribe medicine (51%) and those who both prescribe and dispense medicine including 
contraceptive methods such as the IUD, pills and DMPA injections (49%). 
 
The physicians in this study cannot be characterized as “family planning service providers.”  
They are all for-profit private practice physicians whose clinical practice involves either 
general primary care services (principally curative services) for the MBBS physicians, or 
obstetrical care for the OB/GYN specialists.  These providers operate out of small clinics, 
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usually consisting of a waiting area and a single consultation room without laboratory 
facilities on site.  The results indicate that family planning services are more likely to be 
provided by the OB/GYN specialists than the MBBS:  approximately three out of every four 
OB/GYN specialists (76%) reported that they provide a full range of family planning services 
to their patients, as opposed to fewer than one in every 10 (7%) of the MBBS physicians.    
 
Key Results from Providers’ Survey 
 
• Eighty-eight percent of the 158 private 
practice physicians were interviewed 
8-12 months after they had attended an 
EngenderHealth training session on 
DMPA. 
• Sixty percent of the physicians in the 
study are OB/GYN specialists and 40 
percent are MBBS (n=139) 
• Average daily caseload: OB/GYN = 25 
patients, MBBS = 48 patients 
• The three most common reasons given 
for participating in the study and the 
EngenderHealth seminar: Believe 
DMPA is a good method (21%); Gain 
more knowledge about family planning 
(19%); Peer pressure to attend (16%). 
• About two-thirds of the physicians 
(63%) reported that the 
EngenderHealth seminars were “very 
useful.” 
• Sixty-five percent of the physicians 
interviewed reported that their clinical 
practice changed as a result of 
participating in the study/attending the 
EngenderHealth seminar. 
• Eighty-one percent of the physicians 
reported either regularly counseling 
patients about DMPA or 
providing/prescribing the method. 
• Almost all of the physicians (92%) 
accurately reported one or more 
techniques for managing common side 
effects of DMPA use. 
• Thirty-seven percent of the physicians 
correctly reported that fertility 
normally returns within six months 
after discontinuing use of DMPA. 
Each of the physicians in the study took part in 
one or more of the professional seminars 
organized by EngenderHealth.  The three most 
frequently cited reasons for participating in the 
seminars and study were 1) a belief that DMPA 
is a good contraceptive method (21%); 2) to 
gain more knowledge about the national family 
planning program (19%); and 3) peer pressure 
to attend due to the seniority of the trainers 
(16%).  The majority of the physicians (63%) 
reported that the EngenderHealth seminars were 
“very useful,” principally because of the 
contraceptive technology update information 
that was presented by the trainers (52% of all 
physicians cited “latest knowledge” as the 
principal reason for finding the seminar useful 
to their medical practice).  Approximately two-
thirds of the 139 physicians (65%) reported that 
their clinical practice changed as a result of 
taking part in the study.   
 
Approximately one-fifth (17%) of the 
physicians in this study reported that before 
taking part in the DKT social marketing 
program and EngenderHealth seminars they had 
prescribed or otherwise provided NetEn to one 
or more of their patients.  After taking part in 
the study the large majority (81%) of the 
physicians interviewed reported having 
provided, prescribed or counseled one or more 
patients about DMPA. The average number of 
patients that the physicians in the study reported 
who were currently using DMPA injectables 
was 10.  There is a substantial difference in the 
mean number of DMPA users by type of 
provider:  MBBS physicians reported a mean of 
only 5.3 DMPA users while OB/GYN 
specialists reported a mean of 13.3 DMPA 
users.   
 
The findings from the survey of physicians’ technical knowledge cannot be attributed to the 
EngenderHealth professional seminar/training program, because the study did not obtain a 
baseline indicator of the participating physicians’ knowledge before the study began, nor did 
it include a comparison group of physicians who did not participate in the seminars.  
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However the findings on the level of physician technical knowledge are indicative of their 
capacity to provide quality services.  About two-thirds of the physicians in the study (62%) 
gave only a single correct answer as to the time a woman can begin using DMPA (e.g., some 
physicians were unclear about when a woman should begin if she were breastfeeding, had 
had an abortion or was not between the first and seventh day of menstruation).  The large 
majority of the physicians in the study knew the principal mechanisms of action that DMPA 
exerts to avoid pregnancy.  Physicians’ knowledge of the disadvantages and side effects of 
DMPA are about the same level as their knowledge of the benefits.  Approximately three-
quarters (75%) of the physicians in this study gave between one and four disadvantages of the 
three-month injectable contraceptive method.  The large majority (approximately 89%) of the 
physicians in the study reported knowing between one and five side effects, most commonly 
citing amenorrhoea (49%) and weight gain (35%).    
 
Almost all of the physicians in the study (92%) accurately reported one or more techniques 
for managing bleeding problems caused by DMPA, and about one-quarter (24%) reported 
three or more things that they could do to assist women in managing this most commonly- 
cited disadvantage of the contraceptive method.  However, important differences did emerge 
in the number of management techniques that MBBS physicians reported as compared to 
OB/GYN specialists:  approximately one-fifth of the MBBS physicians (18%) could not 
suggest a single technique for managing bleeding disorders, whereas only one OB/GYN 
physician (approximately 1% of the sample) could not cite a management technique.   
 
When physicians were asked to list what they considered to be major contraindications to 
DMPA use, the responses indicated a mixed level of understanding about the method 
specifically and family planning in general.  Approximately one-fifth to one-sixth of the 
physicians in the study (15% - 20% range) gave medically correct responses, (e.g., 
hypertension, breast cancer, diabetes or liver disease).  The result that approximately 10 
percent of the physicians in the study reported that DMPA was contraindicated for newly 
married or nulliparous women suggests that a small but important proportion of physicians do 
not support the use of contraceptives for delaying the first birth.   
 
Results: First-Time DMPA Users 
 
A total of 352 first-time DMPA clients agreed to take part in the follow-up interview during 
the three-month enrollment period of April-June 2000.  These clients formed the sample for 
this study.  The lost to follow-up rate for the subjects of this study is substantial (48%).  In 
part this is due to the fact that one-third of the sample (36%) gave address information that 
was incorrect or incomplete.  The reader is therefore cautioned against assuming broad-based 
generalizations from these findings.  The results are informative of the experience of a small 
group of first-time DMPA users seen by private practice physicians in three urban centers of 
Gujarat and are remarkably similar to results from a 1998 study of DMPA users conducted by 
the Population Council.   
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All of the women in the study were married and the large majority (88%) reported that their 
husbands had not been away for a single night during the last six months.  The average age of 
the sampled women was 27 years.  Relatively few women in this study have not attended any 
school and almost one-half (approximately 44%) 
reported they had completed either high school or 
higher secondary, and an additional 24 percent 
had completed graduate or post-graduate school.  
The women in the study reported that their 
husbands’ educational levels are comparable to 
their own.   Almost all of the wives reported that 
their husbands are employed (99.5%) most 
commonly in a petty business (36%) or service 
industry position (42%).   
Key Results form Survey of First-
Time DMPA Users 
ularities). 
 
• Only 52 percent of the 352 DMPA 
users were successfully interviewed 
seven months after receiving the first 
dose; the high lost to follow-up rate 
limits the ability to generalize the 
findings. 
• Clients in the study are older (mean 
age is 27 years) and fairly well 
educated (43% have completed level 
beyond secondary) and have used 
contraceptives before (41% since last 
pregnancy). 
• About one-half (51%) of the clients 
said that before beginning DMPA 
they were told about its side effects, 
and 62 percent were told about a 
warning sign (indicating a need to 
see a physician). 
• Almost all of the DMPA users (91%) 
correctly knew its effective use 
duration. 
• Eighty-seven percent reported 
experiencing one or more side 
effects from DMPA (most 
commonly menstrual irreg
• Seventy percent of women who 
experienced side effects sought help 
from a physician. 
• By the time of third dose only 27 
percent of the first-time users 
continued with the method. 
• Fifty-five percent of the DMPA 
discontinuers had successfully 
switched to another method. 
• The seven-month DMPA 
discontinuation rate of 73 percent 
among women in this study is 
comparable to results from other 
follow-up studies of DMPA users 
conducted in Uttar Pradesh, India 
(81% at time of the 4th dose) and the 
Philippines (69% at 15 months). 
• Results suggest that women in this 
study are willing to pay between 
Rs.55-84 for the DMPA injection, 
excluding consultation fees. 
 
The first-time DMPA users in this study have a 
low parity, with the average number of living 
children being 1.6 (SD plus or minus 0.9).  
Approximately one-quarter (27%) of the women 
who recently began using DMPA reported that 
they desire to have another child.  These findings 
suggest that the majority of the DMPA users 
either do not desire any more children or are 
undecided about their reproductive intentions.  
Slightly less than one-half of the first-time DMPA 
users (41%) reported that since their last 
pregnancy they had tried another contraceptive 
method before switching to DMPA.  The methods 
most frequently used before starting DMPA were 
the IUD (50%) and oral contraceptives (34%).   
 
Approximately three out of every four first-time 
DMPA users reported that the first discussion to 
begin using DMPA was initiated by the 
physician.  When asked to rate the degree to 
which they thought the physician had encouraged 
using DMPA, only 7 percent of the women said 
“very much” and over one-third (37%) said the 
doctor had been neutral or even discouraging.  
Almost one-half (47%) of the first-time DMPA 
users reported that the physician had encouraged 
her “somewhat.”  A minority of the women (30%) 
who began using DMPA indicated that they 
would have preferred using another contraceptive 
method instead of DMPA.  Among these women, 
the most frequently cited alternative method was 
the IUD (57%) followed by oral contraceptives 
(29%) and tubal ligation (9%).   
 
Only one-quarter (24%) of the first-time DMPA 
users said that they had been advised about the 
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possibility of switching to another method before starting to use DMPA.  However, about 
one-half of the women (51%) who began using DMPA during this study reported that they 
were told about the possible side effects before receiving the first injection.   Less than one-
half (41%) of the DMPA users said that they had been informed what to do if they 
experienced one or more of the side effects.   The overall impression from these findings is 
that a slight majority of the women in this study received sufficient information on DMPA 
side effects before starting to use the method. 
 
The side effect most frequently mentioned by DMPA users was spotting (40%), followed by 
amenorrhoea  (39%), irregular menses and prolonged or heavy bleeding (27% each).  The 
large majority of women who reported experiencing one or more side effects indicated that 
the condition was “very severe” as opposed to “somewhat severe.”  For example, almost all 
of the women who reported heavy bleeding (96%) said the side effect was “very severe.”  
The percentage of women reporting a side effect who sought help from a physician as a 
consequence of the condition was about 70 percent, with as many as 90 percent of the women 
who had prolonged or heavy bleeding saying that they went to seek medical help.  
Approximately 55 percent of the women who sought help from a physician for care of the 
side effect received a check-up and some type of medicine, and an additional 23 percent of 
the women who sought care reported they were told not to worry by the physician after the 
examination because the side effect was minor.   
 
Among the 184 first-time users of DMPA who agreed to take part in this study, a little over 
half (51%) had a second injection, and of those, about the same proportion (54%) had a third 
injection.   In total, 134 of the 184 first-time DMPA users (73%) discontinued use of the 
injectable contraceptive after having one or two doses.  The results from this study are 
comparable to the 1998 DMPA study conducted by the Population Council in Uttar Pradesh.  
In the 1998 study only 19 percent of the DMPA users continued to use the method at the time 
of the fourth dose. The continuation rate is also comparable to data from the Philippines 
where an operations research study conducted by the Population Council showed that by the 
end of a 15-month period, only 31 percent of the original cohort of DMPA users returned for 
a fifth injection.  Clearly the DMPA method is not for all women or even a majority, but after 
a period of trial use it is reasonable to expect that about 20-30 percent of users will continue 
with the method.  In this context, the ability to switch to another method is critically 
important. 
 
Approximately one-half (55%) of the women who stopped using DMPA had switched to 
another contraceptive method.  The majority of these women (51%) switched to another 
method within 15 days after discontinuing with the injectable method. At the time of the 
interview the large majority of the women who had stopped using DMPA but had begun 
using another method (85%) were still using the same contraceptive method begun after 
DMPA.  An additional 10 percent were still using family planning but had switched again to 
another contraceptive method.   In all, only 60 of the 184 first-time DMPA users in this study 
(33%) stopped using contraceptive methods entirely after discontinuing use of the injectable 
contraceptive method after the first, second or third dose. 
 
The average amount paid by the DMPA users for a single ampule was Rs. 103, excluding the 
physician’s consultation fees.  This amount is substantially more than the Rs. 84 that women 
in the study indicated as the maximum reasonable amount that could be charged for the 
ampule.  It is almost twice as much as the Rs. 55 that these women reported as being 
affordable to pay for a single DMPA ampule.   





The ability of this study to generate recommendations is limited by the special characteristics 
of the physicians who took part in the DKT India program in Gujarat, the high loss to follow-
up rate among the DMPA clients, and the small sample size.  Therefore the following points 
are offered as tentative recommendations for program managers to consider as they work 
towards expanding contraceptive choice for women in India. 
 
• The DMPA injectable contraceptive should be offered through social marketing 
programs in India in conjunction with professional support services, such as IEC 
materials and professional development opportunities.  OB/GYN specialists may be a 
more appropriate category of physicians for reaching women with family planning 
services in general. 
 
• The price of DMPA should be reduced from the current procurement price of Rs. 75 
per ampule that NGOs pay the supplier to an amount that provides a maximum retail 
price for the client of about Rs. 40-55. 
 
• DMPA should be made available in multiple service delivery systems (e.g., other than 
social marketing or private sector settings) that can ensure provider technical 
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BACKGROUND 
The national family welfare program in India does not currently include injectable 
contraceptives in its mix of contraceptive methods offered in public sector clinics.  Although 
both types of injectable contraceptives (NetEn and DMPA) are approved for commercial sale by 
the Drug Controller of India and are available with a doctor’s prescription, the Ministry of 
Health and Family Welfare has not begun routine procurement of either contraceptive method.  
There has not been a large body of research on the use dynamics of injectable contraceptives in 
India that could be used to guide policy decisions on the addition of the method.  The few 
studies that have been conducted indicate positive results and are hence suggestive of an 
important role the method could assume in the national family planning program.   
 
Pharmacia & Upjohn conducted a “Post Marketing Surveillance Study on Injection Depo-
Provera”3 that was designed to assess the safety and acceptability of DMPA among a sample of 
1,079 women.  The large majority of these women (84.2%) continued with the method through 
five doses.  Side effects were common, as almost 80 percent of the subjects in this study 
reported experiencing one or more medical events during the study period, though only three of 
these cases were considered serious.  The conclusion from this 1999 study is that “DMPA 
150mg is a safe and effective contraceptive, and that sufficient pre-treatment counseling on the 
expected hormonal effects will greatly increase the acceptability of this method of 
contraception” (PMS Final Report, page 2). 
 
In 1998 the Population Council’s Asia and the Near East OR/TA Project conducted an 
operations research study on the effect of price changes on perceptions and use of DMPA in 
Uttar Pradesh in association with Parivar Seva Sanstha.4  This study examined patterns of use 
when three different prices were charged for the DMPA method in the clinics of an affiliate of 
Marie Stopes International.  Although overall continuation with the method was observed to be 
low, with less than one-fifth (19%) of the women continuing through four doses, users’ 
perceptions were positive and those who could not tolerate a side effect were able to switch to 
another, more acceptable method.  A wholesale price of Rs. 35 was estimated as being the most 
affordable price for the DMPA in the setting of this study.  These two studies are recent 
investigations into the use dynamics of DMPA in India.  
 
Public debate on injectable contraceptives is still characterized by strident rhetoric that often 
polarizes discussions.  This has restricted the implementation of a large-scale, national program 
for injectable contraceptives in India.  However, many public, NGO and private sector service 
delivery systems are suitably matched to the requirements of providing injectable contraceptives, 
including the ability to ensure choice and service delivery quality.  This operations research 
study was designed to demonstrate the feasibility of providing injectable contraceptives in 
private medical practices and to contribute to the body of scientific literature on the acceptability 
of this method in India.    
                                                 
3 “Post Marketing Surveillance Study of Injectable Contraceptive Depo-Provera in Indian Women,”  R. P. 
Soonawala, David Zambrano and F. Tam.  Pharmacia & Upjohn.  October 8, 1999.  New Delhi, India. 
4 “Analysis of Price Change on the Perceptions and Use of DMPA among Clients Using Reproductive Health 
Services in Uttar Pradesh, India.”  Leila Caleb-Varkey, John W. Townsend, Sneh Vishwanath and Sudha 
Tewari. The Population Council. March 27, 1998. New Delhi, India. 
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STUDY INTERVENTION 
The conduct of operations research to investigate issues surrounding the introduction of DMPA 
into a family planning system required the participation of partner agencies that bring 
specialized skills and services.  The study required two essential components for its intervention:  
1) access to a fairly large number of physicians supported by a contraceptive distribution system 
that includes DMPA in its method mix; and 2) training and supportive supervision skills to 
ensure good quality counseling and informed choice of the injectable contraceptive method. 
Two leading international agencies formed a partnership to conduct this operations research 




The DKT social marketing programs in India have been at the forefront of exploring alternative 
contraceptive options and delivery systems.  DKT India is a leader in this field and has a proven 
record in establishing sustainable marketing systems for oral contraceptives and condoms 
(among other products) in several states.  DKT India first included injectable contraceptives in 
its program in 1996 when NetEn was piloted in a social marketing project in Maharashtra and 
Gujarat.  In 1999, the distributor of DMPA in India, Pharmacia & Upjohn, began to offer the 
contraceptive at Rs. 70 to NGOs (down from the commercial rate of Rs. 150 per ampule).  This 
reduced price brought the method within affordable range for social marketing programs, and in 
1998 and 1999 DKT began to introduce the method into its programs in Maharashtra and 
Gujarat.  DKT was acutely aware of the concerns from special interest groups in India about 
ensuring informed choice of the injectable contraceptive and had built into its program from the 
beginning an investment in IEC materials and supportive supervision by regional sales 
representatives and state level IEC officers.  The partnership with FRONTIERS was an 
extension of their program to bring the additional benefit of information on use dynamics and 
provider motivation.   
 
DKT India was responsible for contacting approximately 100 private practice providers in 
Ahmedabad, Baroda and Surat (this number was increased by EngenderHealth in the process of 
arranging for the professional seminars) about participating in the study.  In addition to assisting 
in identifying participating physicians, DKT India provided an uninterrupted source of DMPA 
injectable contraceptives at a subsidized price of Rs. 40 to their stockists (small, local 
pharmaceutical providers who are associated with the DKT India program).  Through the 
network of DKT India sales representatives and IEC program officers in Gujarat, DKT India 




The study identified the need to ensure a baseline level of good communication practices that are 
conducive to improved counseling about DMPA as a critically important element of the study.  
In addition, there was a concern about ensuring a standard level of technical knowledge among 
all the providers in the study.  A partnership was formed with EngenderHealth in India to 
organize these two aspects of the study and to coordinate the design and implementation of the 
professional development seminars and IEC material production with DKT India and 
FRONTIERS.  Funds for the EngenderHealth organized activities were provided through the 
Population Council’s Expanding Contraceptive Choice program.  A final report is available 
from EngenderHealth and the Population Council providing detailed information on the 
activities carried out by EngenderHealth under this subagreement.  This section of the operations 
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research final report provides an overview of the principal accomplishments in the training and 
supervision of the private practice providers who participated in the study.  
 
EngenderHealth developed and field tested training materials for physicians and paramedical 
staff in collaboration with DKT India during October 1999.  As part of this collaboration these 
two agencies produced a series of IEC materials on DMPA that included a client take-away 
brochure, an awareness-raising poster, a self-instructional flip chart for use in physicians’ 
waiting rooms, and laminated instruction sheets for physicians (specifying technical points about 
the method, including contraindications, side effects and their management).  The client-oriented 
materials were translated into Gujarati and Hindi and printed by DKT, and then distributed by 
DKT sales representatives to all of the participating physicians after their training program. 
 
The study originally called for a series of two-day in-service training programs for the private 
practice physicians.  However, it soon proved impossible to convene these physicians for more 
than a one-day (six hour) session because almost all were unavailable or unwilling to close their 
practices for more than one day.  Therefore, EngenderHealth, working with locally recruited and 
respected consultants, organized eight one-day training programs that functioned as a type of 
professional development seminar for the 241 physicians.  Among these physicians, 159 agreed 
to participate in the operations research study at the end of the seminar.  As a consequence of the 
reduced number of days devoted to upgrading the physicians’ communication and technical 
practices, the study decided to concentrate remaining resources on enhancing the supervision 
skills of the DKT India sales representatives and IEC officers.  EngenderHealth conducted  a 
one-day training session for 43 DKT staff between January and May 2000.  This short course 
was designed to upgrade the technical knowledge and communication skills related to DMPA 
and to provide practical guidance to the DKT India sales force on how to interact with 
physicians on the need to ensure informed choice of DMPA.  In addition to conducting the 
training programs for physicians and DKT India staff, EngenderHealth staff and consultants also 
conducted follow-up visits with all 159 physicians who took part in the seminars between 
February and June 2000.  These follow-up visits served to ensure that the physicians received a 
continuous supply of DMPA, to facilitate proper infection prevention and safe disposal of 
sharps, and to address any questions that the physicians raised about DMPA or the study.   
 
STATEMENT OF THE PROBLEM 
 
The overall goal of the proposed project was to expand the availability of contraceptives in 
India, particularly temporary contraceptives.  The study sought to demonstrate the feasibility 
of providing the DMPA injectable contraceptive to private sector medical clients in a manner 
that promotes informed choice, adheres to good technical quality, and supports sustained use 
by satisfied clients.  Prior to this study there had not been a follow-up investigation of first-
time DMPA users from private practice medical settings in India.   
 
The long-term goal of this study is to ultimately contribute to the reduction of maternal mortality 
and morbidity in India through an increase in contraceptive practice/contraceptive choice.  The 
following are the short term or immediate objectives of the study: 
 
1. The study will demonstrate the feasibility of providing the DMPA injectable 
contraceptive to private sector clients in a manner that promotes informed choice, 
adheres to good technical quality and supports sustained use by satisfied clients. 
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2. The study will identify factors that motivate private sector physicians to provide 





The research utilized a post-test only, uncontrolled study design that retrospectively investigated 
the contraceptive practices of all first-time DMPA users in private practice settings that 
participate in the DKT India contraceptive social marketing program in Gujarat.  Physicians 
were able to purchase DMPA contraceptives from DKT India suppliers at a subsidized rate of 
Rs. 40 (commercially available DMPA is sold for approximately Rs. 150).   In addition to 
purchasing the DMPA at a reduced rate, the physicians also benefited from promotional and IEC 
materials produced by the study, and regular visits by sales representatives and other 
representatives of DKT India.  Three sites were purposively selected for the study:  Ahmedabad, 
Baroda and Surat.  At the time of the study design these were the principal locations of the DKT 
program in Gujarat.  
  
There were three conditions placed on the physicians who agreed to take part in the study that 
were outlined in an informed consent statement administered by EngenderHealth and DKT India 
staff before enrolling any physician in the study.  First, they had to participate in a day-long 
professional seminar on interpersonal communication/counseling techniques and a contraceptive 
technology update on DMPA, organized by EngenderHealth.  Second, the physicians had to 
agree to request the consent of all first-time DMPA users for a follow-up interview seven 
months later, and to record sufficient locater information on a specially-designed client locator 
card to conduct the home interview.  Third, the physicians agreed to a short interview conducted 
in their office approximately six months after the EngenderHealth professional seminar.  
  
A very modest one-time stipend was paid to all of the physicians to ensure that they recorded 
locator information (the same amount was paid regardless of the number of DMPA clients 
enrolled in the study).  The original proposal called for 100 physicians to be enrolled in the 
study, but once field operations began, this number was expanded to 159 (in order to achieve a 
larger sample of first-time DMPA users), and later dropped to 158 when one physician moved. 
  
Physicians who participated in the study conveyed to all first-time DMPA users a standardized 
informed consent statement (written in Gujarati and Hindi) that outlined the principal objectives 
of the study, described the follow-up interview at the woman’s home in seven months (i.e., after 
receiving three doses of DMPA), and asked for her permission to record her name and contact 
information.  DMPA clients were considered eligible for the study if they had never used an 
injectable contraceptive previously (but could have used another contraceptive method), were 
resident in the nearby vicinity of the physician’s practice, and had the intention to remain at their 
present address for 9-12 months.  Client enrollment began on April 1, 2000 and continued 
through September 30, 2001.  Representatives of CORT collected the client enrollment cards on 
a monthly basis throughout the enrollment period.   
  
A subagreement was issued to CORT for the organization and conduction of the client and 
provider surveys.  The study’s six-month data collection period began fieldwork operations on 
November 1, 2000 and continued without interruption until late January 2001.  All of the first-
time DMPA users who enrolled in the study during April–June 2000 and approximately 75 
percent of the 158 providers had been contacted for interviews by that date.  On January 26, 
2001, a severe earthquake occurred in Gujarat, devastating many areas of the state and 
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substantially damaging large portions of Ahmedabad and Surat, with less physical destruction in 
Baroda.  The earthquake had multiple effects on the client follow-up study, primarily through 
the profound disruption to daily life even in the study areas that were not directly afflicted with 
the destruction.  These overwhelming environmental effects caused the follow-up interview 
period to be truncated and the elimination of all clients from the study who had been enrolled 
between July and October 2001.  The remaining interviews with physicians continued after a 
pause, as the remainder of these cases were in Baroda and other areas less affected by the 
earthquake, and the indicators measured in the provider survey were less likely to be disrupted. 







In all, 158 private practice physicians who participated in the DKT-sponsored contraceptive 
social marketing program in Gujarat agreed to participate in the study of DMPA use 
dynamics.  This section reviews the principal findings from a survey of these providers 
conducted 9-12 months after they attended a training session on interpersonal communication 
techniques and a contraceptive technical update on DMPA. 
 
Table 1: Age distribution of the private practitioners enrolled in DMPA project by place of 
practice, sex, and specialty (percentage) 








































































































































TOTAL %  24% 41% 35% 51% 49% 40% 60% 100% 
Approximately 88 percent of these physicians (n=139) were successfully contacted and 
completed the interviews during this study.  Among the 19 physicians who did not fully 
respond to the interviews, two (1% of the total sample) refused to answer the interviewer’s 
questions, one could not be contacted (0.6% of the total sample), one physician had passed 
away (0.6% of the total sample), and 15 had moved out of the study sites and were lost to 
follow-up (approximately 10% of the total sample).  Overall, the response rate in the study 
was strong and there is no indication that the missing 12 percent of the original sample in any 
way substantially biases the results presented here. 
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The sample of physicians was nearly evenly divided by gender: 71 of the respondents were 
male and 68 were female.  Almost two-thirds (60%, n=83) were OB/GYN specialists and all 
Table 2: Private practitioners’ years of experience and type of health services provided by 
place of practice, sex, and specialty (percentage) 
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of the others (40%, n=56) were MBBS, or generalists.  Among the OB/GYN specialists, 69 
percent were female, whereas most (80%) of the MBBS physicians were male (Table 1).  
Approximately two-thirds of the physicians in the study were between the ages of 30 and 49 
and an additional one-quarter were between the ages of 50 and 59.  There is no significant 
difference in the age of physicians by sex or specialty, but the physicians from Ahmedabad 
were somewhat younger than those from Surat or Baroda.  
 
The average length of time that physicians in this sample had been providing medical 
services was quite long (17.4 years), corresponding to the middle-aged characteristic of the 
sample’s majority (Table 2).  The average length of time a physician in the sample had been 
working in the private practice setting where the interview took place was about 12 years.  
Physicians from Ahmedabad had been providing health care services for a shorter length of 
time (in general, and in the current setting) than providers in the other two study sites, 
reflecting their younger age (Table 1).  Otherwise, there are no apparent differences in the 
length of time that physicians have been practicing medicine in any type of setting by their 
sex or specialty.   
 
Figure 1: Average case load of private medical 












Male Female MBBS OB/GYN





















The percentage of physicians who currently provide honorary medical services differs by the 
location of their practice:  physicians from Ahmedabad are more likely to provide pro bono 
care (38%) than physicians from Surat (25%) or Baroda (35%).  In addition, female 
physicians are more likely than male physicians to provide honorary medical care (37% 
versus 28%, respectively), as are OB/GYN specialists as opposed to MBBS physicians (43% 
versus 16%).  Although in general the sample is almost evenly divided between physicians 
who only prescribe medicine (51%) and those who both prescribe and dispense medicine 
(including contraceptive methods such as the IUD, pills and DMPA injections) (49%), there 
are important differences according to the location of the physician’s practice, their sex and 
specialty.  Physicians in Ahmedabad were more likely to only prescribe medicine (70%) than 
their peers in Baroda (46%) or Surat (44%).  Male physicians were less likely to only 
prescribe medicine (38%) than female physicians (65%), which is also reflected in the finding 
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that OB/GYN physicians (who are predominately female) are more likely to prescribe only 
(74%) than MBBS physicians (18%).    
 
The average case load of the physicians in the study varied according to their type of 
specialty and sex:  the predominately male MBBS physicians reported a higher daily case 
load (mean number of patients per day = 40.4 for male providers and 47.9 for MBBS 
providers) than the predominately female OB/GYN providers (mean number of patients per 
day = 28.4 for female providers and 25.5 for OB/GYN specialists).  In general, the providers 
in these settings have a high caseload, particularly considering that most operate in a single-
practitioner clinic without secretarial or nursing support (Table 3). 
 
Approximately two-thirds of the 
physicians in this study (66%) 
work in a solo-practice setting, 
with almost all of the MBBS 
physicians (91%) working alone.  
Anecdotal evidence indicates that 
in settings where there are two 
physicians (approximately one-
quarter of the sample), they are 
husband and wife. Table 3 
reports that settings with more 
than one physician are most 
likely to be OB/GYN practices.   
The majority of the practices do 
employ a nurse (60%), but a high 
percentage do not have nursing 
staff (approximately 40%).  
While MBBS providers are least 
likely to have any nursing staff in 
their practice, they are almost as 
likely to have an administrative 
support person in their clinic as 
an OB/GYN specialist.  
However, OB/GYN specialists 
are more likely to have more 
nurses and administrative staff  
(mean of 3.5 and 2.2 per 
physician, respectively) than an 
MBBS provider (mean of 2.1 and 
1.3, respectively, per physician). 
Table 3: Staff available in the clinics of the private 
practitioners (percentage) 


























































































































Family Planning Service Provision 
 
The physicians in this study cannot be characterized as “family planning service providers.”  
They are all for-profit private practice physicians whose clinical practice involves either 
general primary care services (principally curative services) for the MBBS physicians, or 
obstetrical care for the OB/GYN specialists.  These providers operate out of small clinics, 
usually consisting of a waiting area and a single consultation room without laboratory 
facilities on site.  The provision of contraceptive methods is a complementary service that is 
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provided to their patients.  The results presented in Table 4 show that family planning 
services are more likely to be provided by the OB/GYN specialists than the MBBS:  
approximately three out of every four OB/GYN specialists (76%) reported that they provide a 
full range of family planning services to their patients as opposed to fewer than one in every 
10 (7%) of the MBBS physicians.    
 











Provide IUD, OCP, DMPA, Condom method 
All of the above services 




















































Don’t know/can’t say 
Not providing any FP services 
 































*  Multiple responses possible 
 
However, almost two-thirds of the MBBS physicians (68%) indicated that they do provide 
family planning counselling to their patients. Approximately one-half of all the physicians in 
the study reported that both the patient and the provider are equally likely to initiate 
discussions about the use of family planning during the consultation.   Important differences 
emerge from the findings in the overall proportion of patients that the physicians reported as 
usually receiving family planning information.  Forty-two percent of patients seen by 
OB/GYN specialists are told about family planning, whereas only 25 percent of the MBBS 
physicians’ patients received this information.  Overall, the physicians report that about one-
third of their patients routinely receive information about family planning methods and 
services.  This finding reinforces the anecdotal evidence that this study’s sample is not 
strongly oriented toward the provision of family planning services.  
 
Participation in the EngenderHealth Seminars   
 
Each of the physicians took part in one or more of the professional seminars organized by 
EngenderHealth (described previously in this report).  The principal reasons given by the 
physicians for participating in the seminars and their appreciation of these meetings are 
indicated in Table 5. 
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Table 5: Participation in the EngenderHealth seminars (percentage) 














Motivating reason to get involved in 
DMPA OR study* 
It’s a new method 
For more knowledge about FP 
program 
Peer pressure  
Excellent information for me and 
my patients 
Respect for EngenderHealth 
Convenient method/easy to use/low 
failure rate 
Want a reliable method for lactating 
mother/for women’s health 
Self interest 
Better way of FP 






































































































































Reason for considering course 
useful/ not useful 
Informative/more knowledge/latest 
knowledge 
Have new option for patient 
Low failure rate/few side 
effects/safe and convenient method 
Easy for the patients 
We can use all methods 
Patients refuse to take injection 
Useful for doctor to know 
It has side effects 





























































































Percent practitioners agreeing that 
participating in programs like this 






















































Percent who knew about DMPA 
before the EngenderHealth 
session 
Yes 






































Number of private practitioners 
attended EngenderHealth 
information session 
34 56 48 55 83 138 
Percent who reported that the 
information session added to their 
existing knowledge about DMPA 
74 93 90 100 80 86 
    *  Percentage adds to more than 100 due to multiple responses 
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The three most frequently cited reasons for participating in the seminars and study were: 1) a 
belief that DMPA is a good contraceptive method (21%); 2) to gain more knowledge about 
the national family planning program (19%); and 3) peer pressure to attend due to the 
seniority of the trainers (16%).  The last reason was reported by a large proportion of younger 
physicians from Ahmedabad: 38 percent of the physicians from Ahmedabad reported this as a 
reason for attending, compared to only about eight percent of the physicians from Baroda and 
Surat.  The older physicians from Baroda and Surat were more likely to cite appreciation of 
learning new technical information on injectable contraceptive methods as the third most 
important reason for attending.    
 
The majority of the physicians (63%) reported that the EngenderHealth seminars were “very 
useful,” principally because of the contraceptive technology update information that was 
presented by the trainers (52% of all physicians cited “latest knowledge” as the principal 
reason for finding the seminar useful).  Approximately one-third of the MBBS physicians 
(38%) did not know about DMPA before attending the seminars and a similar proportion of 
the OB/GYN physicians (36%) indicated that their knowledge about DMPA was incomplete 
before the study.  It is interesting to note that although the majority of the physicians reported 
the seminar as being either very useful or useful, a majority (approximately 56%) disagreed 
with the statement “participating in programs like the EngenderHealth seminars enhances 
professional growth.”  The phrase “enhancing professional growth” was possibly a source of 
misunderstanding among some of the survey’s respondents as other findings show that almost 
all of the physicians (87%) reported that their technical knowledge of DMPA was improved 
as a result of the seminar. 
 
Other findings clearly indicate 
the perceived benefit and 
usefulness of the 
EngenderHealth seminars for 
physicians’ clinical practices 
(Figure 2).  Approximately two-
thirds of the 139 physicians 
(65%) reported that their clinical 
practice changed as a result of 
taking part in the study, and an 
almost equal proportion (70%) of 
those who self-reported a change 
indicated that they are more 
likely to counsel patients and 
provide DMPA as a consequence 
of the EngenderHealth and DKT 
program. 




Counsel in general and 
provide DMPA: 34%
Provide DMPA & 
counsel specific to FP:  
36%
Counsel in general 
more frequently:  30%
n= 139
n= 90
Did you change your practice as a 
result of participating in the study? If so, how?
  
Provision of Injectable Contraceptives (NetEn and DMPA) 
 
Prior to the operations research study, DKT was supplying NetEn (two-month injectable 
contraceptive) to physicians in Gujarat as part of its social marketing program.  Although 
DMPA was available through commercial outlets, the method was relatively unknown and 
substantially more costly than the two-month injectable.   
 
   




(17%) of physicians reported 
that they had prescribed or 
otherwise provided NetEn to 
one or more of their patients 
before the study (Figure 3).  
These physicians were more 
likely to be OB/GYN 
specialists (26% of this group 
reported providing NetEn to 
patients before the study) 
than MBBS (only 4% of this 
group reported having 
previously provided NetEn).  
After taking part in the study, 
the large majority (81%) of 
physicians interviewed 
reported having provided, prescribed or counselled one or more patients about DMPA.  
MBBS and OB/GYN specialists were almost equally likely to do so:  71 percent of the 
MBBS and 88 percent of the OB/GYN specialists indicated that they provided one or more 
type of DMPA service (not shown).  
Figure 3: Have you ever counseled a 
patient about, or provided an 















Before the study After the study





Table 6: Number of DMPA clients reported by physicians (percentage) 
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The average number of patients that physicians reported as currently using DMPA injectable 
was approximately 10 (Table 6).  However, about one-third of the physicians (30%) reported 
having between 11 and 50 current DMPA users among their patients.  There is a substantial 
difference in the mean number of DMPA users by type of provider: MBBS physicians 
reported a mean of only 5.3 DMPA users while OB/GYN specialists reported a mean number 
of 13.3 DMPA users.  The physicians in Ahmedabad reported a higher mean number of 
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Knowledge of DMPA Injectable Contraceptive 
 
The findings from the survey of physicians’ technical knowledge cannot be attributed to the 
EngenderHealth professional seminar/training program because the study did not obtain a 
baseline indicator of the participating physicians’ knowledge.  However, findings on the level 
of their knowledge are indicative of the capacity to provide quality services to women who 
seek out DMPA from these private practice physicians.  In addition, even though no causal 
linkage can be established between the EngenderHealth training and the physicians’ 
knowledge, a plausible case can be made that the intervention would have contributed to 
technical knowledge and improved clinical practice (as suggested by the previous findings on 
physicians’ reported changes in clinical practice as a result of taking part in the study).   
 
Table 7: Physicians’ knowledge about timing and mechanism of action (percentage) 














Time when a client should start on 
DMPA 
Between first and seventh day of 
menstruation 
Anytime after seven days of 
menstruation with backup contraceptive 
Six weeks postpartum for breastfeeding 
mother 
Immediately after MR/abortion 
Confirm no sign and symptoms of 
pregnancy 










































































Number of correct responses 
1 
2 

























Knowledge about the mechanism of 
action of DMPA 
Suppress ovulation/reduce production of 
hormones necessary for ovulation 
Causes thickening of cervical mucus 
acting as a barrier to sperm 
Makes endometrium thin reducing chance 
of implanting fertilized egg 
Do not know 





























































Number of correct responses 
1 
2 


























The majority of physicians (77%) reported that a woman should start using DMPA between 
the first and seventh day of menstruation (Table 7).  About two-thirds of the physicians in the 
study (62%) gave only a single correct answer as to the time a woman can begin using 
DMPA (e.g., some physicians were unclear about when a woman should begin if she were 
breastfeeding, had had an abortion, or was not between the first and seventh day of 
menstruation).  The large majority of the physicians in the study knew the principal 
mechanisms of action that DMPA exerts to avoid pregnancy:  83 percent reported it 
suppresses ovulation and 43 percent reported it causes a thickening of cervical mucus.  In 
addition, about one-third of the physicians (30%) indicated that it inhibits implantation 
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through an effect on the endometrium.  About 80 percent of the physicians knew one or two 
mechanisms of action.  There were not large differences in the level of knowledge between 
MBBS physicians and OB/GYN specialists, although the specialists were more likely to 
report three or more correct responses on the timing and mechanisms of action.  There are no 
substantial differences in the level of physicians’ knowledge by the location of their practice 
(Ahmedabad, Baroda or Surat). 
  














Major advantages of DMPA * 
Requires no daily routine  
Long acting 
Can be safely used by women 
Easy to use 
Reversible method 
Can be used confidentially 
No effect on lactation 
Requires no action in sexual intercourse 
Most effective contraceptive  
Provides health benefits 
No advantage 
Others (correct responses) 






































































































































Non-contraceptive health benefits of 
DMPA* 
Reduced risk of vaginal yeast infection 
Reduced risk of endometrial cancer 
Reduced risk of acute PID 
Reduced symptoms of endometriosis 
Reduced risk of ectopic pregnancy 
Less bleeding, reduced anaemia 
Reduced frequency and severity of sickle 
cell disease crisis 
No non-contraceptive health benefit 
Others (correct responses) 















































































Number of non-contraceptive health 









































*  Percentage adds to more than 100 due to multiple responses 
 
The majority of the physicians (approximately 57%) reported between one and five major 
advantages of DMPA, and approximately one out of six physicians knew eight to 10 
advantages (Table 8).  The most commonly cited advantage of the three month injectable is 
that it requires no daily routine, followed by its long-acting properties, safety and ease of use.  
A little over two-thirds of the physicians (69%) reported between one and four non-
contraceptive benefits of DMPA, most commonly citing reduced risk of vaginal yeast 
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infection and endometrial cancer.  Although both MBBS and OB/GYN specialists had strong 
levels of knowledge about the advantages and non-contraceptive benefits of DMPA, the 
OB/GYN specialists were more likely to cite more advantages and benefits than the 
generalists.  The physicians from Ahmedabad (who are more likely to be younger than 
physicians from Baroda or Surat) cited more advantages and benefits than physicians from 
the other study sites.  Over one-half of the physicians from Ahmedabad cited between six and 
10 advantages (approximately 59%), compared to only 24 percent and 39 percent of the 
physicians from Baroda and Surat.  The results in Table 9 illustrate comparable differences in 
the proportion of physicians citing multiple non-contraceptive benefits across the three study 
sites as well.    
 
Table 9: Physicians’ knowledge of the disadvantages and side effects of DMPA 
(percentage) 













Disadvantages of DMPA 
Prolonged or irregular bleeding 
Amaenorrhea 
Menstrual changes 
No protection against STIs/HIV  
Action cannot be stopped immediately 
Takes longer for fertility to return 
Weight gain 
No disadvantages/refusal to answer 
Others 













































































































Others (correct responses) 
No problems 

























































































Menstrual changes resulting due to 




Prolonged or heavy bleeding 
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The results presented in Table 9 indicate that physicians’ knowledge of the disadvantages and 
side effects of DMPA are commensurate with their knowledge of the benefits.  Three-
quarters of the physicians in this study gave between one and four disadvantages of the three-
month injectable contraceptive method.  The two most commonly cited disadvantages were 
prolonged or irregular bleeding (63%) and amenorrhea (60%).  There were similar 
differences in the number of disadvantages cited by physicians in the three study sites as were 
noted in the distribution of responses about advantages:  physicians in Ahmedabad were more 
likely to cite more disadvantages than were physicians in Baroda or Surat.  A comparable 
pattern regarding potential side effects of DMPA use is shown in Table 10.  The large 
majority (approximately 89%) of physicians knew between one and five side effects, most 
commonly citing amenorrhoea (49%) and weight gain (35%).  In response to a question 
asking for more detailed information on the type or nature of menstrual changes that may 
occur as a result of using DMPA, the physicians in this study exhibited a fairly strong level of 
technical knowledge:  almost all of the physicians (95%) reported at least one or two possible 
changes, most often citing irregular bleeding (65%) or amenorrhoea (63%). 
 















Ways to manage* 
Through counseling before use  
Ongoing counseling during use 
Treatment using OCP, hormones 
Treatment using non-steroid 
Stop use of DMPA and switch to 
another contraceptive method 
Treatment using ibuprofen 
Next DMPA injection earlier 
Others  






































































































*  Percentage adds to more than 100 due to multiple responses 
 
Almost all of the physicians in the study (92%) accurately reported one or more technique for 
managing bleeding problems caused by DMPA, and about one-quarter (24%) reported three 
or more alternatives to assist women in managing this most commonly cited disadvantage of 
the method (Table 10).  Providing counselling was the most frequently given management 
technique, both before beginning the method (60% of the physicians said this was important) 
and during initial use (39% of the physicians indicated this was an important aspect of the 
clinical management of bleeding disorders).  In other results (not shown) the reliance upon 
counselling by the physicians is also evident:  approximately 73 percent reported that 
counselling the patient is an important technique for managing amenorrhoea.  Approximately 
one-third of the physicians (30%) indicated that oral contraceptives or another type of 
hormonal medicine might be used to manage bleeding, or that the woman could stop using 
DMPA and switch to another method if the bleeding was too much for her to manage 
successfully (Table 10).  There were no substantial differences in the responses to this 
question by providers in the different study sites.  However, important differences did emerge 
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in the number of management techniques that MBBS physicians reported as compared to 
OB/GYN specialists:  approximately one-fifth of the MBBS physicians (18%) could not 
suggest a single technique for managing bleeding disorders, whereas only one OB/GYN 
physician (approximately 1% of the sample) did not cite a management technique.   
 






















Currently taking hormones for medical 
condition 
Newly married/nulliparous 






























































































*  Percentage adds to more than 100 due to multiple responses 
 
When physicians were asked to list what they considered to be major contraindications to 
DMPA, use the responses indicated a mixed level of understanding about the method 
specifically, and family planning in general (Table 11).  Approximately one-fifth to one-sixth 
of the physicians in the study (15 – 20%) gave medically correct responses (e.g., 
hypertension, breast cancer, diabetes or liver disease).  Slightly more than one-sixth of the 
physicians (approximately 17%) did not report any contraindications to DMPA use (which is 
different than not giving any response and is tantamount to saying “don’t know” in the 
context of this question’s wording).  Interestingly, OB/GYN specialists were more likely to 
report that there are no contraindications to DMPA use than MBBS physicians (25% versus 
5%).  This finding suggests a shortcoming in the some physicians’ knowledge about DMPA.  
The result that approximately 10 percent of the physicians in the study also reported that 
DMPA was contraindicated for newly married or nulliparous women suggests that a small 
but important proportion of physicians do not support the use of contraceptives for delaying 
the first birth.  Other findings not shown in the tables reveal other shortcomings in the 
physicians’ knowledge.  For example, only 37 percent of the sample correctly reported that 
fertility normally returns within six months after discontinuing DMPA.   
 
DMPA Availability and Cost to Physicians  
 
Physicians who participated in this study had access to a DKT sponsored stockist who sold 
them DMPA ampules at a highly subsidized price (as described above).  Each physician was 
visited on several occasions by DKT sales representatives and informed where the stockist 
was located.  Stockists were conveniently located nearby all of the physicians in the study, 
and patients could be referred to the stockist for the purchase of the DMPA injection with a 
prescription, although fewer than one out of six physicians actually referred patients.  Almost 
three-quarters (70%) of the physicians in the study preferred to maintain a stock of the 
injectable contraceptive in their clinic for sale to their patients (Figure 4).  Figure 4 also 
shows that about one-sixth of the physicians who agreed to take part in the study had not yet 
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prescribed DMPA to a single patient in the eight months since the EngenderHealth seminar.  
Results (not shown) indicate that MBBS physicians were 50 percent less likely to have 
provided DMPA to a patient (21% versus 11% of OB/GYN specialists).  These physicians 
were more likely to be in Baroda (21%) than in Ahmedabad (9%) or Surat (13%).   

















       
Figure 5: Price paid by physicians for 
a single DMPA ampule
41-50 Rs.
7%





40 Rs. or less
81%





Under the terms of the study, DKT committed to provide DMPA ampules at a cost of Rs. 40 
to participating physicians for the life of the study.  (The regular subsidized price of Rs. 75 
that DKT provides was further reduced in order to more closely match the worldwide rate for 
DMPA provided by many international donors.)  The large majority of physicians (81%) 
reported purchasing the DMPA injectable for Rs. 40 (Figure 5).  The remaining physicians 
purchased ampules at a higher price, but did not report the source of the purchase.  Results 
(not shown) indicate that the average maximum amount physicians believe women would be 
willing to pay for DMPA is Rs. 75, whereas the average affordable amount that physicians 
believe women could pay is about Rs. 72.  
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DMPA Client Results 
 
A total of 352 first-time DMPA clients agreed to take part in the follow-up interview during 
the three-month enrollment period of April – June 2000.  These clients formed the sample for 
this study.  Table 12 presents the results of the interview process. 
 
Table 12:  Sample results of first-time DMPA clients 
Sample Results Percentage Total (n) 
Completed interview 52%  184 
Lost to follow-up: incorrect address 36%   88 
Lost to follow-up: change of residence 8%  29 
Lost to follow-up: unavailable after three 
contact attempts 13%   45 
Refused interview 2%  6 
Total number enrolled during April – June 
2000 100%  352 
 
The lost to follow-up rate for the subjects of this study is substantial.  This is due, in part, to 
the fact that more than one-third of the sample’s (36%) address information was incorrect or 
incomplete.  The external validity of the study (i.e., ability to generalize the findings to all 
first-time DMPA clients seen by private practice providers) is severely constrained because a 
large proportion (approximately 48%) of the original sample failed to take part in the follow-
up interviews.  The reader is therefore cautioned against assuming broad-based 
representativeness and advised to consider the following results as informative of the 
experience a small group of first-time DMPA users seen by private practice physicians in 




All of the women in the study were married and the large majority (88%) reported that their 
husbands had not been away for a single night during the last six months.  The average age of 
the sampled women was about 27 years; the youngest was 18 and the oldest was 50 (Table 
13).  Over one-quarter were over 30 years of age, and there is no substantial difference in the 
age of women between the three study sites.  Relatively few women had not attended any 
school, almost one-half (approximately 42%) reported they had completed either high school 
or higher secondary, and an additional 24 percent completed graduate or post-graduate 
school.  They reported that their husbands’ educational levels are comparable to their own, 
with about 41 percent of husbands having completed high school or higher secondary school 
and about one-third (31%) having completed graduate or post-graduate education.  Almost all 
of the women (99.5%) reported that their husbands are employed, most commonly in a petty 
business (36%) or service industry position (42%).  About 14 percent reported that they are 
also employed (“working for money”) (not shown).  A large majority (80%) of the women in 
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Wife’s Education completed 
None 
Primary (classes 1-5) 
Middle (classes 6-8) 
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The findings presented in 
Figure 6 show that the first-
time DMPA users have a low 
parity, with the average n
of living children being 1.6 
(SD plus or minus 0.9).  
Almost one-half of the sample 
(47%) were either nulliparous 
or had just one child, while 50 
percent had two or three 
children and the remaining 
three percent had four or more.  
Almost 11 percent of women 
reported having lost a child 
(not shown).  The average 
number of induced abortions 
among women in this sample is 1.4.  Approximately 36 percent of the women interviewed 
reported having had at least one, and an additional 17 percent reported having at least one 
spontaneous miscarriage (not shown).   



















Approximately one-third (32%) of first-time DMPA users in this study had their last 
pregnancy within the 12 months preceding the interview, and an additional one-third (35%) 
had their last pregnancy between one and two years previous to the interview (Table 14).   
About three-quarters of the women reported that their last pregnancy ended in a live birth 
(73%), while about one-sixth (16%) indicated they had an induced abortion to terminate the 
pregnancy.  Other findings (not shown) revealed that approximately 24 percent of women 
who had a pregnancy within the past year had a health problem that caused them to seek 
medical care from a physician.   The results in Table 14 indicate that approximately one-
quarter (27%) of the women who 
recently began using DMPA 
reported that they desired to have 
another child, most commonly 
just one more (84% of those who 
desired another).  Among those 
who do want another child, 46 
percent indicated that they want 
to wait one to three years before 
becoming pregnant, whereas 
about one-quarter (28%) said 
they would wait three to five 
years.  These findings suggest 
that while the majority of the 
DMPA users either do not desire 
any more children or are 
undecided about their 
reproductive intentions, a small 
but important number of first-
time DMPA users are using the 
method for spacing purposes.   
 
Table 14: Past pregnancy and future intentions 
(percentage) 
 TOTAL 
Timing of last pregnancy (n=184) 
No pregnancy 












Outcome of last pregnancy (n=184) 











Percent want to have more children (n=184) 27 
Total number of children desired (n=50) 





Time when they would like to have next child (n=50) 
< 1 year  
1-3 years 
3-5 years 
> 5 years 
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Contraceptive Use Dynamics before Starting DMPA and Decision Making Influences on 
DMPA Use 
 
Slightly less than one-half of first-time DMPA users (41%) reported that they had tried 
another contraceptive method since their last pregnancy before switching to DMPA (Figure 
7).  The methods most frequently used were the IUD (60%) and oral contraceptives (34%).  
This finding indicates that one-half of DMPA users may actually be switching from a long-
acting, inexpensive method (IUD) and bears further investigation.  Approximately one-third 
of the DMPA clients reported having received a copy of the brochure on DMPA (34%) or 
having seen one of the posters on DMPA (36%) produced and distributed in the study.  
Apparently there was uneven distribution or use of the IEC materials by physicians in the 
three cities, as clients from Ahmedabad were more likely to report having received a 
brochure (43%) than clients in Baroda (37%) or Surat (13%).  However, clients from Baroda 
were more likely to have seen a poster on DMPA in their physician’s office (58%) than were 
clients from Ahmedabad (30%) or Surat (20%). 
 
Figure 7: Contraceptive use dynamics 





Did you use another contraceptive 
before starting with DMPA since 
your last pregnancy?
If yes, which 








The results presented in Figure 
8 clearly indicate the important 
role physicians assumed in 
assisting women in making the 
decision to begin using DMPA.  
Approximately three out of 
every four women reported that 
their first discussion on DMPA 
use was initiated by their 
physician.  About one-sixth of 
the women in the study (17%) 
said that they began the 
discussion about DMPA use. 
There was some variation in 
these findings across the three 
study sites:  fewer women in 
Baroda indicated that the 
physician initiated discussion 
(68%) about DMPA than 
women in Ahmedabad (82%) 
or Surat (83%). However, the 
majority of the study’s 
respondents in each setting 
indicated that physicians began 
the discussion of DMPA use.  
Although these results indicate 
that physicians were proactive 
in describing DMPA to the 
women in their practices, other 
findings (not shown) reveal 
women’s perceptions about this 
advice.  When asked to rate the 
degree to which they thought 
the physician had encouraged  
Figure 8: Who initiated the discussion 
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DMPA use, only seven percent of the women said “very much,” and over one-third (37%) 
said the doctor had been neutral or even discouraging.  Almost one-half (47%) of first-time 
DMPA users reported that the physician had encouraged her “somewhat”  (the remaining 9% 
reportedly couldn’t remember the level of encouragement they had received from the 
physician). 
 
A minority of the women 
(30%) who began using 
DMPA indicated that they 
would have preferred using 
another contraceptive 
method instead of DMPA 
(Figure 9).  Among those 
women, the most 
frequently cited alternative 
method was the IUD 
(57%), followed by oral 
contraceptives (29%), and 
tubal ligation (9%).  In 
other findings (not shown), 
a pronounced difference in the preference of another method by study site emerges, as a 
much larger proportion of women in Ahmedabad indicated a desire to begin using the IUD 
(77%) than women in Baroda (47%) or Surat (41%).   Additionally not a single respondent in 
Ahmedabad reportedly desired a tubal ligation, whereas 18 percent of the DMPA users in 
Baroda and 12 percent of the DMPA users in Surat indicated that they would have preferred 
to have a sterilization procedure done instead of having an injectable contraceptive 
administered by the physician.  
Figure 9: Contraceptive method 
preference at time of first DMPA use
37%
63%
No Yesn= 184 n= 56
Would you have preferred to use 
another method than DMPA when you 
began using the injectable 
contraceptive?
If yes, which 








Knowledge about DMPA 
Table 15: Information given at the time of first injection (percentage) 
 TOTAL (n=184) 
Told about the possibility of switching to another method 24 
Told about the possible side effects before beginning the use of DMPA 51 














Informed about what to do if experience any of the possible side effects 41 
Told about problems that indicate one should come back to the clinic (apart from coming to the 
clinic for the regular injections) 62 
Queries about DMPA were answered to complete satisfaction 85 
Know the correct interval (in months) between DMPA injections 98 
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Only one-quarter (24%) of first-time DMPA users said that they had been advised about the 
possibility of switching to another method before starting to use DMPA (Table 15).  
However, about one-half of the women (51%) who began using DMPA during this study 
reported that they were told about the possible side effects before receiving the first injection.   
The most frequently mentioned side effects discussed with the provider were amenorrhoea 
(45%), spotting (24%) and heavy bleeding (22%).  Slightly less than one-half (41%) of the 
DMPA users said that they had been informed what to do if they experienced one or more of 
the side effects, but almost two-thirds (62%) reported that they had been told of one or more 
particular conditions that indicate return to the physician for follow-up care. 
   
These findings reflect two perspectives on clients’ knowledge about how to manage side 
effects and indicate that around one-half of all clients know what to do if they experience a 
side effect from DMPA.  Taken together with the finding that 51 percent of users reported 
being told about side effects, the overall impression is that a small majority of women who 
received DMPA from the physicians in this study received sufficient information on side 
effects.  However, most of the first-time DMPA users said that all of their questions had been 
answered to their complete satisfaction (85%).  Almost all of the DMPA users (98%) were 
able to correctly report the number of months that should elapse before receiving another 
injection. 
 
Experience with Side Effects 
 
 Even though about one-half of the 
women who began using DMPA 
during this study received 
information about side effects, the 
large majority (87%) reported 
experiencing one or more side 
effect sometime during the period 
of DMPA use (Figure 10).  
Approximately one-quarter (23%) 
of the DMPA users said that they 
experienced three or four side 
effects. 
 
The side effect most frequently 
mentioned by DMPA users was spotting (40%), followed by amenorrhoea (39%), irregular 
menses, and prolonged or heavy bleeding (27% each) (Table 16).  The large majority of 
women who reported experiencing one or more side effect indicated that the condition was 
“very severe” as opposed to “somewhat severe.”  For example, almost all of the women who 
reported heavy bleeding (96%) said the side effect was very severe.  Only weight gain was 
more frequently indicated as being less than very severe (40% “somewhat severe” as opposed 
to 37% “very severe”).  The percentage of women reporting a side effect who sought help 
from a physician was about 70 percent, with as many as 90 percent of those who had 
prolonged or heavy bleeding saying that they sought medical help.   
Figure 10: Number of side effects DMPA 
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Table 16: Nature of side effects experienced by DMPA users after one to three doses 
(percentage) (multiple responses possible) 
Severity of the side effects 
experienced (n=184) 
Percent who sought 
help from their 
provider (n)  
Percent reporting 
side effects 
(n=184) Very severe Somewhat severe  
Spotting 40 61 30 72 (74) 
Prolonged or heavy bleeding 26 96 4 90 (48) 
Amenorrhoea 39 75 20 82 (71) 
Irregular menses 27 76 18 74 (50) 
Weight gain 19 37 40 43 (35) 
Others 18 47 50 59 (34) 
Approximately 55 percent of the women who sought help from a physician for a side effect 
received a check-up and some type of medicine, and an additional 23 percent reported they 
were told not to worry as the side effect was minor (results not shown).  When asked to 
indicate which of the side effects they experienced was the most troublesome, women in this 
study were most likely to report amenorrhoea (32%) or prolonged or heavy bleeding (26%). 
The changes in menstrual patterns affected many of these women’s abilities to perform 
religious activities.   
 
Continuation with the Second and Third Doses of DMPA 
 
Results that provide information on continuation rates among DMPA users are presented with 
a caveat about the small sample size and limited ability to draw firm conclusions or 
generalize the results to larger populations.   
  
Among the 184 first-time users 
of DMPA who agreed to take 
part in this study, a little over 
one-half (51%) received a 
second injection.  Of those, 
about the same proportion 
(54%) had a third injection 
(Figure 11).   This means that 
between the first and second 
doses, and second and third 
doses, approximately one-half 
of all users decided to 
discontinue use of the method.  
By the time the women had 
reached the decision to take the 
fourth injection (i.e., at the time 
of the interview), about three-quarters of those who took a third dose (74%, n=50) stated an 
intention to continue using DMPA.  In total, 134 of the 184 first-time DMPA users (73%) 
decided to discontinue use of the injectable contraceptive after one or two doses.  The 
principal reasons given by women for discontinuing DMPA after the second or third dose 
Figure 11: Continuation of DMPA 




























Dose of DMPA received
(n= 184) (n= 184)(n=184)
 Introducing DMPA Injectable Contraceptives to Private Medical Practitioners in Urban Gujarat 
25 
was an inability to tolerate the side effects of menstrual disorders, (75-80% of the reasons 
cited).   
 
Table 17: Use of other contraceptive methods after stopping DMPA 
(percentage) 
 TOTAL (n=74) 
















Time when started using this method after discontinuing the DMPA 
injection 












Percent currently using 
Same method switched to after the DMPA 
Method other than the one first tried to after the DMPA 







Approximately one-half (55%) of the women who stopped using DMPA switched to another 
contraceptive method such as oral pills (32%), condoms (26%), IUD (15%), or a permanent 
method (tubal ligation 8% or vasectomy 3%) (Table 17).  The majority of women who 
switched to another method (51%) did so within 15 days after discontinuing the injectable 
method. At the time of the interview, the large majority (85%) of women who had stopped 
using DMPA but had begun using another method were still using the same contraceptive 
method begun after DMPA.  An additional 10 percent were still using family planning but 
had switched again to another method.  In total, 60 of the 184 first-time DMPA users in this 
study (33%) stopped using contraceptive methods entirely after discontinuing use of the 
injectable after the first, second or third dose (not shown). 
 
Cost of DMPA as Reported by First-Time DMPA Users 
 
The results presented in Table 18 suggest that cost savings to physicians (who were provided 
ampules by DKT stockists at the subsidized price of Rs. 40) were not, in fact, passed on to 
clients.  The average amount paid by the DMPA users for a single ampule was Rs. 103, 
excluding physician’s consultation fees (Table 18).  This amount is substantially more than 
the Rs. 84 that women in the study indicated as the maximum reasonable amount they would 
pay per ampule.  It is almost twice as much as the Rs. 55 that these women reported as 
affordable for a single DMPA ampule.  There is a large discrepancy between the amount paid 
by DMPA clients per ampule and the amount paid by physicians (Figure 5).  Almost three-
quarters of the physicians indicated that they routinely pay on average Rs. 48.  Apparently 
physicians are imposing a surcharge to their clients for the contraceptive.   
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 Table 18: Cost of DMPA (Rs.) reported by users (percentage) 
 TOTAL (n=184) 
Amount paid for the DMPA excluding consultation fees 
≤ 50 
51-100 
101 – 200 
≥ 201 











103 ± 57 
20 – 350 














84 ± 59 
10 – 500 
















55 ± 56 
10 – 500 
UTILIZATION 
 
The results from this study will be disseminated through a series of targeted briefings and 
specialized summaries for key decision makers in the Indian national family planning 
program.  Attention will be given to reaching individuals and groups working in different 
sectors, including social marketing agencies, non-governmental organizations, donors, and 
the Ministry of Health and Family Welfare (central and state level authorities).  FRONTIERS 
will collaborate with the USAID Mission in New Delhi, DKT India and EngenderHealth to 
conduct targeted briefings.  In addition to these briefings and small group meetings, 
FRONTIERS will work through the Population Council network of informed journalists to 
insert key findings, or to commission topical articles in leading daily newspapers in Delhi and 
in the three cities targeted by the study.  The dissemination of key findings within a context 
of informed choice and expanding contraceptive options to women will lead to sharing 
information with a wide audience. 
 
The dissemination strategy will have multiple objectives.  The study’s findings will be used 
to contribute to on-going discussions within the MOFW about the addition of DMPA to the 
national family program, and to stimulate discussion within selected states about conducting 
a limited introduction program.  Social marketing agencies working in India will be presented 
results from the study that demonstrate how DMPA can be successfully introduced into 
private practice medical settings.  
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CONCLUSIONS AND RECOMMENDATIONS 
 
First-Time DMPA Users  
 
There are several limitations on the results from this study that constrain the internal and 
external validity of the client findings.  The principal outcome indicator that drove the study 
design was assessment of discontinuation rates of first-time DMPA users who obtained the 
method in private clinical practices.  Because the caseload of eligible DMPA clients was 
smaller than anticipated, the ability to calculate life table analysis was of borderline strength, 
even considering a very high response rate.  The January 2001 earthquake restricted access to 
almost 60 percent of the sample of enrolled first-time users, obviating the ability to provide 
any information on continuation that could be considered representative of all DMPA users 
seeking care from the private practice physicians in this study, or for other groups of DMPA 
users of similar characteristics in India.  A second limitation on the study’s results is due to 
the high lost to follow-up rate (48%).  This was caused by the physicians’ failure to note 
sufficient information on the client locator card at the time of enrollment in the study.  The 
high non-response rate limits the ability to generalize results even to the sample of first-time 
patients who agreed to take part in the study.  In conclusion, the study presents information 
on the experiences of the 184 first-time users who responded to the survey, and all 
conclusions must necessarily be drawn only about that group of women and no others.   
 
After taking into consideration the two principal limitations on the client–related findings, the 
study is able to provide several very interesting insights into the experience these women had 
with the DMPA contraceptive method.  Because of the study’s limitations, it is important to 
consider the social and economic characteristics of the women who responded to the 
interviewer’s questions.  This group of first-time DMPA users were, on average, in their late 
20s, well-educated and low parity, with employed husbands.  The majority of these women 
did not want any more children, but slightly less than one-half reported having used a 
contraceptive method since their last pregnancy.  They came to know about DMPA during 
visits to their physicians.  The IEC materials were effective in reaching women with 
information about DMPA – about one-third of the DMPA users reported seeing one or both 
of these materials.  However, brochures and posters were unevenly distributed, which 
apparently limited women’s exposure to their messages.   
 
Three-quarters of the women in this study reported that the physician first brought to their 
attention the possibility of trying DMPA.  The proactive role of physicians can be a cause of 
concern if the provider exerts undue influence or pressures the woman to accept the method.  
This was not the case among women in this study, perhaps because of their educational level 
or because of the private practice setting where the physicians operate.  In any case, one out 
of three DMPA users reported that the physician was neutral in his remarks about trying 
DMPA, while an additional 47 percent indicated that the physician had only been 
“somewhat” encouraging.  These findings indicate that physicians acted responsibly in their 
promotion of the DMPA method during the study, reaching as many of their patients as 
possible with information on DMPA but not exerting pressure on women to accept the 
method.   
 
The information provided to women about DMPA before they began use was fairly complete, 
yet there was clearly room for improvement.  For example, about one-quarter of the clients 
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said they had been told about the possibility of switching to another method before beginning 
DMPA.  This may have been due to the providers’ perception that these women already knew 
about how to switch to another method (given their previous contraceptive use history and 
educational level) but nevertheless, this message is a standard element of counselling.  More 
troubling is the finding that only about one-half of the first-time DMPA users reported being 
told about potential side effects and what to do if they experienced a side effect.  A large 
majority of the first-time DMPA users did, in fact, experience side effects: 87 percent said 
they had one or more unwanted effects and 70 percent of those sought medical care as a 
consequence.  The high incidence of side effects had a direct effect on the women’s decisions 
to continue using DMPA.   
 
Of the 184 first-time DMPA users contacted seven months after their first dose, only about 
one-quarter were still using the method.  Not all of the women who had taken three doses of 
DMPA (27% of the original 184) indicated that they were going to take a fourth dose as well 
– only about one in five of the original users were expected to take the fourth injection.  
These results show that after an initial steep decline after two to three doses, the number of 
discontinuers probably levels off.  These results are comparable to the 1998 DMPA study 
conducted by the Population Council in Uttar Pradesh where only 19 percent of the DMPA 
users continued to use the method at the time of the fourth dose.  In addition, the continuation 
rate is comparable to data from the Philippines where an operations research study conducted 
by the Population Council showed that by the end of a 15-month period only 31 percent of 
the original cohort of DMPA users returned for a fifth injection.5  Clearly the DMPA method 
is not for all women, or even a majority, but after a period of trial use it is reasonable to 
expect that about 20-30 percent of users will continue with the method.  In this context, the 
ability to switch to another method is critically important. 
 
The majority (55%) of women who tried DMPA but found the side effects intolerable 
switched to another contraceptive method.  About one-third of the women who stopped 
DMPA were not using another method at the time of the interview.  It is plausible that these 
women were simply waiting to resume normal menstrual cycles after stopping DMPA and 
would eventually begin using another method (given their previous contraceptive use 
histories, educational levels, and reproductive intentions).   
 
Although none of the women in this study specifically stated that the cost of the DMPA 
injection was an element in their decision to stop using the method, the average amount that 
these women reported paying for the DMPA injection (Rs. 103) was substantially more than 
the mean cost that was indicated as affordable (Rs. 55), and the mean cost that was judged to 
be reasonable (Rs. 84).  DKT India provided the injectable contraceptive to physicians in the 
study for Rs. 40.  There is a large discrepancy between the amount that physicians paid for 
the DMPA ampule and the amount clients say they paid for the contraceptive.  This 
difference could be due to providers adding a fee, or to clients reporting an inflated price; it is 
impossible to tell.  However these results suggest a client willingness to pay between Rs. 55 





                                                 
5 “DMPA Monitoring Study: Findings on Use and Continuation Rates.”  Population Council ANE OR/TA 
Project Final Report. September 1995. 
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Health Care Providers 
 
The majority of the private sector physicians in this study were OB/GYN specialists and had 
been practicing medicine for some time – on average about 17 years.  There is a notable 
incidence of physicians in the study donating some portion of their time to providing 
honorary medical services, in part reflecting the strong sense of community purpose that 
exists throughout Gujarat.  These physicians work in busy settings with a high daily caseload.  
On average, the MBBS physicians reported seeing 48 patients per day and the OB/GYN 
physicians saw 25 patients per day.  About two-thirds of these physicians work in solitary 
practice settings.  Three-quarters of the OB/GYN physicians reported that they routinely 
provide family planning services as part of their medical practice, but less than one-tenth of 
the MBBS physicians provided family planning services before the study. 
 
Although the physicians in this study were not available to take part in a two-day training 
program, they did seem to appreciate the abbreviated one-day professional seminar that 
EngenderHealth organized.  About two-thirds of the physicians reported the daylong seminar 
as being “useful,” and the large majority (87%) reported that they learned something new 
about DMPA as a result of attending the meeting.  An impressive two-thirds of physicians 
who were interviewed stated that they changed some element of their medical practice as a 
direct result of participating in the EngenderHealth seminar.  These results, and other findings 
reported in the EngenderHealth final report, suggest that even though private practice 
physicians are not easily accessible for in-service training, immediate benefits do accrue from 
condensed, well-prepared training programs.  
 
Before the study began, very few of the physicians had provided an injectable contraceptive 
(less than one-fifth reported having counselled a patient or prescribed NetEn).  After taking 
part in the EngenderHealth seminar and gaining access to the DKT India supply of DMPA, 
fully 81 percent of the physicians counselled patients or prescribed DMPA.  At the time of 
the interviews (about nine months after the EngenderHealth training), the physicians in the 
study reported an average of 10 current users of DMPA in their practices.  Although the study 
was not able to confirm this number, the finding does suggest that after receiving even a brief 
training, and with a continuous supply of the DMPA method, private practice physicians will 




The ability to generate recommendations is limited by the special characteristics of the 
physicians who took part in the DKT India program in Gujarat, the high loss to follow-up rate 
among DMPA clients, and the small sample size.  Therefore, the following points are offered 
as tentative recommendations for program managers to consider as they work towards 
expanding contraceptive choice for women in India: 
 
• The DMPA injectable contraceptive should be offered through social marketing 
programs in India, in conjunction with professional support services such as IEC 
materials and professional development opportunities.  OB/GYN specialists may be a 
more appropriate category of physicians for reaching women with family planning 
services in general. 
 
 Introducing DMPA Injectable Contraceptives to Private Medical Practitioners in Urban Gujarat 
30 
 Introducing DMPA Injectable Contraceptives to Private Medical Practitioners in Urban Gujarat 
31 
• The price of DMPA should be reduced from the current procurement price of Rs. 75 
per ampule that NGOs pay the supplier to an amount that provides a maximum retail 
price for the client of between Rs. 40 and 55. 
 
• DMPA should be made available in multiple service delivery systems (e.g., other than 
social marketing or private sector settings) that can ensure provider technical 
competence and informed choice, including the provision of other temporary 
methods. 
 
 
